Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Repurposing drugs for disease modification in multiple sclerosis
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Interferon-β-1b: a review of its use in multiple sclerosis.
Molecular characterization of a peripheral receptor for cannabinoids.
Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)
Gray matter SWI-filtered phase and atrophy are linked to disability in MS .
Glatiramer acetate (GA) prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway.
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
Teriflunomide for multiple sclerosis.
Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
Adaptive myelination from fish to man.
Biologics-induced autoimmune diseases.
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
Focal vibration in neurorehabilitation.
199 Outcomes after microvascular decompression for patients with trigeminal neuralgia and suspected multiple sclerosis.
ARESTIN®
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™ (peginterferon beta-1a)
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
β-Amyloid: Enemy or Remedy?

Pages